Skip to main content Accessibility help

Amisulpride-induced neuroleptic malignant syndrome

  • Jana Knific (a1) and Ales Kogoj (a2)


Corresponding author

Dr Ales Kogoj, Psychogeriatric Department, University Psychiatric Hospital, SI-1260 Ljubljana Polje, Slovenia. Tel: +386 1 5872 506; Fax: +386 1 5872 590; E-mail:


Hide All
1.Herrera-Estrella, M, Apiquian, R, Fresan, A, Sanchez-Torres, I. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study. BMC Psychiatry 2005:5:22.
2.Atbasoglu, EC, Ozguven, HD, Can Saka, M, Goker, C. Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome. J Clin Psychiatry 2004;65:17241725.
3.Bottlender, R, Jager, M, Hofschuster, E, Dobmeier, P, Moller, HJ. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry 2002;35:119121.
4.American Psychiatry Association. Diagnostic and statistical manual for mental disorders, 4th edn. Washington DC: American Psychiatry Association, 1994.
5.Sachdev, P, Mason, C, Hadzi-Pavlovic, D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatry 1997;154:11561158.


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed